Cardiol Therapeutics (CRDL) Restructuring Costs (2020 - 2021)
Cardiol Therapeutics' (CRDL) quarterly Restructuring Costs came in at $1.2 million in Q2 2021, up 125.41% YoY from $515073.0 in Q2 2020, and up 125.41% on a QoQ basis from $515073.0 in Q2 2020.
Cardiol Therapeutics (CRDL) Restructuring Costs (2020 - 2021) Analysis & Trends
Cardiol Therapeutics (CRDL) has 2 years of Restructuring Costs data on file, last reported at $1.2 million in Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - |
| 10 | Cardiol Therapeutics | 212.73 Mn | 193.88 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 1.16 Mn |
| Jun 30, 2020 | 515,073.04 |